SEC Comment Letter 0000000000-23-009806 to Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc.
Date: Sept. 5, 2023 · CIK: 0001419041 · Accession: 0000000000-23-009806
AI Filing Summary & Sentiment
File numbers found in text: 333-274257
Letter
United States securities and exchange commission logo September 5, 2023 Paul Wagner, Ph.D. Chief Executive Officer Forte Biosciences, Inc. 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 Re:Forte Biosciences, Inc. Registration Statement on Form S-3 Filed August 29, 2023 File No. 333-274257 Dear Paul Wagner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Dan Koeppen, Esq.
Show Raw Text
United States securities and exchange commission logo
September 5, 2023
Paul Wagner, Ph.D.
Chief Executive Officer
Forte Biosciences, Inc.
3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
Re:Forte Biosciences, Inc.
Registration Statement on Form S-3
Filed August 29, 2023
File No. 333-274257
Dear Paul Wagner:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Dan Koeppen, Esq.